Catalyst Q1 revenue $98.5M (+15.4% YoY); AGAMREE launch adds $1.2M

CATALYST PHARMACEUTICALS, INC.

2024-Q1 EPS reported $0.19 revenue$98,509,000

Total Q1 2024 net product revenue $98.5M, up 15.4% YoY; FIRDAPSE net revenue $66.8M (+16.2%).
AGAMREE contributed $1.2M net revenue in first two weeks of U.S. launch, surpassing initial expectations.
GAAP net income $23.3M ($0.19 diluted EPS); Non-GAAP net income $46.8M ($0.38 diluted EPS).
Cash and cash equivalents $310.4M as of March 31, 2024, a 125.5% increase from year-end 2023.
Full-year 2024 total revenue guidance reaffirmed at $455M-$475M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.